Research programme: metabolic disorders therapy - Alize PharmaAlternative Names: AZP-03 program - Alize Pharma
Latest Information Update: 17 Feb 2010
At a glance
- Originator Alize Pharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 17 Feb 2010 Discontinued for Metabolic disorders in France (unspecified route)
- 13 Feb 2009 Early research in Metabolic disorders in France (unspecified route)